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1. Introduction 
Early embryonic development is a very precise and complicated process. When a sperm 
meets an egg, a series of well-orchestrated changes take place, which end up with distinct 
types of cells that make up an organism. Cells start from a pluripotent state and differentiate 
without changes in DNA sequence. A differentiated cell shares the same DNA sequence 
with the zygote from which it is descended (mammalian B and T cells being an exception). 
The diverse functions of different cells are due to tissue-specific patterns of gene expression, 
which are established during development; once the fates of the cells are decided, they will 
be maintained faithfully through cell divisions. Hence it is reasonable to assert that 
development is, by definition, an epigenetic process (Reik, 2007). The specific gene 
expression programs in differentiated cells are regulated by a more flexible system, which 
dynamically switches on and off the genes for maintaining homeostasis or responding to 
environmental changes. 
Epigenetics is defined as “the study of heritable changes in genome function that occur 
without alterations to the DNA sequence” (Probst, et al., 2009). Epigenetics has been 
suggested as the key regulatory system in early development. Mechanistically, epigenetic 
regulation involves the covalent modification of chromatin components such as DNA 
methylation and histone modifications (acetylation, methylation and phosphorylation are 
the best characterized).  Short and long non-coding RNAs are also part of the epigenetic 
regulatory system because of their role in targeting the chromatin modifications within the 
genome (Hawkins & Morris, 2008; Morris, 2009a). DNA methylation at the cytosine residue 
of CpG dinucleotides is the most studied epigenetic modification in mammals. Its effects on 
genome function underlie a number of physiological phenomena such as genomic 
imprinting and X chromosome inactivation, and it also contributes to the genesis of human 
cancers and to aging. CpG methylation was the only known chemical modification of 
mammalian genomic DNA with an epigenetic role before the discovery of 5-
hydroxymethylcytosine that will be discussed later (Haluskova, 2010; Ohgane, et al., 2008). 
CpG methylation is stable, heritable and reversible, which fulfils the requirement for a 
dynamic regulation system for development. 
DNA methylation is most vulnerable to the environment during early development, because 
the genome methylation pattern is established during this stage and the DNA synthetic rate 
is very high in the early embryo. In mammals, proper DNA methylation is essential for 
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normal development. Aberrant methylation patterns are involved in various developmental 
pathological phenomena and even diseases in adult life that are known under the rubric:  
the Developmental Origin of Health and Disease (DOHaD) (Waterland & Michels, 2007).  
In this chapter, we will discuss the biochemistry of DNA CpG methylation including the 
enzymes catalyzing the process and the controversial pathways of DNA demethylation. The 
dynamics of DNA methylation in early development will be covered as well as the role of 
methylation in cell-lineage determination, imprinting and the genesis of germ cells. We will 
also review the evidence supporting the importance of DNA methylation in DOHaD. 
2. The biochemical mechanism of DNA methylation 
DNA methylation occurs via covalent modification of cytosine by adding a methyl group to 
the carbon-5 of the pyrimidine ring mainly in a 5’-CG-3’ dinucleotide pattern (CpG: C 
phosphodiester G). It is performed by the DNA methyltranferase (Dnmt) enzyme family. All 
identified Dnmts use S-Adenosylmethionine (SAM) as the methyl group (CH3) donor. SAM, 
a biological sulfonium compound, is a major methyl donor involved in a number of 
essential reactions, including DNA, RNA and protein methylation (Lin, 2011).  
The mechanism of DNA cytosine 5-methylation was analyzed for the prokaryotic Dnmt 
M.HhaI, which recognizes the specific sequence of 5’-GCGC-3’ and methylates the first 
cytosine (J. C. Wu & Santi, 1985, 1987). Prokaryotic and eukaryotic Dnmts share a number 
of conserved primary amino acid motifs that are believed to be important both 
structurally and functionally.  
 
Fig. 1. Catalytic mechanism of cytosine methylation by Dnmt.  
The Dnmt performs a nucleophilic attack on the C6, which leads to the formation of a 
covalent intermediate and activation of the C5. The activated C5 performs a nucleophilic 
attack on the methyl donor S-Adenosylmethionine (SAM) to acquire a methyl group from 
SAM. Following the methyl transfer, the C5 proton is eliminated and the intermediate  
is released, yielding the ultimate product: cytosine methylated on C5. Adapted from 
Kumar et al (1994). 
The key features of the catalytic mechanism involve the nucleophilic attack on the carbon-
6 of the target cytosine by a conserved cysteine residue of the enzyme and formation of a 
covalent intermediate (Kumar, et al., 1994) (Fig 1). The process is induced by binding of 
the enzyme to DNA, which turns the target cytosine 180° away from the DNA double 
helix and positions it in the active site with little disturbance to the rest of the DNA 
duplex. The details of this process, termed base flipping, are poorly understood 
(Gerasimaite, et al., 2011; Klimasauskas, et al., 1994; Matje, et al., 2011). The base flipping 
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pulls the target base into closer contact with the enzyme, allowing for the accurate 
recognition of the extrahelical base and the subsequent chemical reactions. The catalytic 
loop of the enzyme, which contains six highly conserved residues, including the catalytic 
nucleophile cysteine residue, moves towards the DNA and stabilizes the extrahelical base 
for methylation (Hermann, Gowher, et al., 2004; Matje, et al., 2011). The nucleophilic 
attack on carbon-6 is performed by the thiol group of the cysteine residue, whereas the 
carbon-5 is relatively unreactive. The positively charged sulfonium ion in SAM makes the 
methyl group that is bonded to the sulfur atom chemically reactive to nucleophilic attack 
(Hermann, Gowher, et al., 2004). The attack leads to the formation of a covalent 
intermediate between the enzyme and the carbon-6 atom of the flipped out target 
cytosine, which results in activation of the carbon-5 atom. The activated carbon-5 
performs a nucleophilic attack on SAM to acquire a methyl group from SAM. Following 
the methyl transfer, the carbon-5 proton is eliminated and the intermediate is released, 
yielding the ultimate product: cytosine methylated on carbon-5 (Hermann, Gowher, et al., 
2004; Klimasauskas, et al., 1994; Kumar, et al., 1994; Yoo & Medina-Franco, 2011). 
3. DNA methyltranferases (Dnmts) 
In mammals, the DNA methylation pattern is set up by three active members of the Dnmt 
family: Dnmt1, Dnmt3a and Dnmt3b. Dnmt3a and Dnmt3b are responsible for the de novo 
methylation that establishes the initial CpG methylation pattern during embryonic 
development, while Dnmt1 is required for maintenance of this pattern, copying the 
information to newly synthesized DNA during replication (Hermann, Goyal, et al., 2004). 
Although structurally similar to other Dnmts, the fourth member, Dnmt2, acts more as an 
RNA methyltransferase (Goll, et al., 2006). Dnmt3-Like protein (Dnmt3L) is a Dnmt-related 
protein that is catalytically inactive, but physically associates with Dnmt3a and Dnmt3b and 
modulates their catalytic activity (Hata, et al., 2002).  
3.1 Dnmt1 
Dnmt1 was the first discovered mammalian DNA methyltransferase (Gruenbaum, et al., 
1982). It is highly conserved among eukaryotes. Dnmt1 is a large single polypeptide that 
comprises 1620 amino acid residues. It contains a large N-terminal domain and a smaller 
C-terminal part, which are connected by a linker of glycine-lysine repeats (Frauer, et al., 
2011).  The N-terminal domain comprises several motifs and is responsible for 
intracellular targeting and regulation of catalytic activity. The C-terminal part harbours all 
ten catalytic motifs that have been identified in bacterial Dnmts (Goll & Bestor, 2005). 
However, studies have shown Dnmt1 exhibited no enzyme activity without the presence 
of its N-terminal domain (Fatemi, et al., 2001; Margot, et al., 2000; Zimmermann, et al., 
1997). In agreement with this, direct interactions between the C-terminal and N-terminal 
parts have been observed and found necessary for Dnmt1 enzyme activity (Fatemi, et al., 
2001; Margot, et al., 2003).   
Dnmt1 is responsible predominantly for the maintenance of DNA methylation information 
through cell divisions. Targeted mutation of the Dnmt1 gene in mice was lethal with 
significantly reduced levels of DNA methylation (E. Li, et al., 1992). The preference of 
Dnmt1 for hemimethylated CpG sites that appear after DNA replication is the key property 
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for this function. After DNA replication, methylated and unmethylated CpG sites are 
transformed into hemimethylated and unmethylated sites, respectively. Dnmt1 shows a 15- 
to 50- fold preference for methylation at hemimethylated sites compared with unmethylated 
sites (Fatemi, et al., 2001; Pradhan, et al., 1999; Zucker, et al., 1985). Dnmt1 acts on 
hemimethylated sites to ensure maintenance of DNA methylation patterns from parental to 
daughter genomes, which also makes it a major target of current pharmaceutical interest. 5-
aza-cytidine, which is an inhibitor of Dnmt1, has been approved by US Food and Drug 
Administration (FDA) for the treatment of all subtypes of myelodysplatic syndromes (MDS) 
(Kaminskas, et al., 2005). 
Dnmt1 was also found to have de novo methylation activity in mouse embryo lysates (Yoder, 
et al., 1997) and CpG island de novo methylation is related to Dnmt1 (Feltus, et al., 2003; Jair, 
et al., 2006). Additionally, Dnmt1 is required for maintenance of methylation in non-CpG 
DNA methylation (Grandjean, et al., 2007). Dnmt1 also interacts with a number of proteins, 
such as methyl-CpG binding proteins, histone deacetylases and histone methyltransferases, 
forming a complicated network regulating chromatin organization and gene expression 
(Kimura & Shiota, 2003).  
3.2 Dnmt2 
Dnmt2 was identified through the analysis of expressed sequence tags (EST) databases 
during a search for de novo DNA methyltransferases in 1998 (Van den Wyngaert, et al., 1998; 
Yoder & Bestor, 1998). Although the existence of all the consensus catalytic motifs strongly 
suggests DNA methyltranferase activity, no catalytic enzyme activity could be detected in 
initial assays. Dnmt2-deficient mouse embryonic stem cells were viable and no obvious 
DNA methylation changes were observed (Okano, et al., 1998b). The function of Dnmt2 
remained enigmatic until a comparatively weak DNA methyltransferase activity was 
demonstrated both in vitro and in vivo (Hermann, et al., 2003; Kunert, et al., 2003; Liu, et al., 
2003; Tang, et al., 2003). 
The weak enzyme activity, however, is not sufficient explanation for the surprisingly 
extensive conservation of Dnmt2 among different species ranging from Schizosaccharomyces 
pombe to Homo sapiens, which indicates an important biological role. Moreover, the 
presence of Dnmt2 is not always accompanied by the presence of DNA methylation, which 
suggests Dnmt2 has additional functions (Schaefer & Lyko, 2009). Studies have uncovered a 
robust transfer RNA (tRNA) methyltransferase activity of Dnmt2 through a DNA 
methyltransferase-like catalytic mechanism (Goll, et al., 2006; Jurkowski, et al., 2008). The 
functional significance of the dual DNA and RNA methyltransferase activity is still 
undiscovered. More work needs to be done to force the closed door of Dnmt2 open.  
3.3 Dnmt3 family 
The Dnmt3 family involves two active enzymes (Dnmt3a and Dnmt3b) and another Dnmt-
like protein (Dnmt3L). Dnmt3a and Dnmt3b were identified in the human and the mouse 
through a search of EST databases using full-length bacterial type II cytosine-5 
methyltransferase sequences. They share similar domain arrangements, including a variable 
region at the N-terminal, which is involved in enzyme targeting, and a C-terminal catalytic 
domain (Chen, et al., 2004).  
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Dnmt3a and Dnmt3b are highly expressed in undifferentiated embryonic stem (ES) cells. 
Though Dnmt3a expression can be readily detected in most adult tissues, Dnmt3b is 
expressed at very low levels in most tissues except testis, thyroid and bone marrow (Okano, 
et al., 1998a; Xie, et al., 1999). The methylation activities of Dnmt3a and Dnmt3b for 
unmethylated DNA and hemimethylated DNA are comparable (Okano, et al., 1998a). 
Inactivation of Dnmt3a and Dnmt3b in mouse ES cells impairs de novo methylation and 
causes postnatal and embryonic lethality respectively. Consequently, they were assigned to 
be responsible for the establishment of DNA methylation pattern during embryogenesis 
(Okano, et al., 1999).  
Encoded by different genes, Dnmt3a and Dnmt3b are functionally overlapping. The 
embryonic defects in mouse ES cells deficient in both Dnmt3a and Dnmt3b are more severe 
than in single mutant mice (Okano, et al., 1999). The two enzymes, however, possesses 
different functions during embryogenesis. Dnmt3b is the major de novo DNA 
methyltransferase detected at embryonic day 4.5-7.0 (E4.5–7.0) in mouse embryonic cells, 
whereas Dnmt3a is significantly and ubiquitously detectable after E10.5 when Dnmt3b is 
below the detection level (Watanabe, et al., 2002). Mutation of Dnmt3b is identified to be 
responsible for a rare autosomal recessive disorder, which is termed as ICF syndrome, 
characterized by immunodeficiency, facial anomalies and centromere instability (Hansen, et 
al., 1999). Dnmt3b also participates in maintaining aberrant hypermethylation in colorectal 
cancer cells, acting cooperatively with Dnmt1 (Rhee, et al., 2002). Lately, high recurrence of 
Dnmt3a mutations has been reported in acute myeloid leukemia (Ley, et al., 2010; Shah & 
Licht, 2011). In addition, certain CpG sites within the Fgf-1 gene locus have been proved to 
be selectively methylated by Dnmt3a in vivo but not by Dnmt3b (Oka, et al., 2006). The 
mechanism and significance of this activity are still undiscovered.  
Although the third member of Dnmt3 family, Dnmt3L, shows a high degree of structural 
similarities of its N-terminal PHD-like zinc finger domain to Dnmt3a and Dnmt3b, it has 
been shown to have no catalytic activity. Key catalytic residues in C-terminal that are 
necessary for DNA methyltransferase activity are missing in Dnmt3L (Aapola, et al., 2000; 
Cheng & Blumenthal, 2008). However, Dnmt3L was reported to play an important role in 
establishment of DNA methylation in maternally imprinted genes in mice (Hata, et al., 
2002). Deletion of the Dnmt3L gene results in aberrant de novo methylation of dispersed 
repeated DNA sequences in male germ cells (Bourc'his & Bestor, 2004). Besides, Dnmt3L has 
been shown to bind and colocalize with Dnmt3a and Dnmt3b in the nuclei of mammalian 
cells. It also stimulates de novo methylation by Dnmt3a in human cell lines (Chedin, et al., 
2002; Hata, et al., 2002).  
4. CpG content and methylation pattern in the DNA of mammalian cells and 
relationship to gene activity 
In mammalian genomes, the abundance of CpG dinucleotides is less than expected on the 
basis of GC content. In human DNA, CpG incidence is only about 25% of what is expected 
considering the base composition (Saxonov, et al., 2006). Moreover, the CpG dinucleotides 
are unevenly distributed in the genome, forming clusters called CpG islands. According to 
the complete genomic sequence of human chromosomes 21 and 22, the CpG islands are 
characterized as DNA regions >500 bp with a GC content >55% and observed 
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CpG/expected CpG of 0.65 (Takai & Jones, 2002). CpG islands occur at or near about 40% of 
mammalian promoters, and play crucial roles in the regulation of gene expression (Fatemi, 
et al., 2005). In accordance with this, bioinformatic evaluation showed a bimodal 
distribution of promoters segregating them into high CpG content and low CpG content 
classes (HCP and LCP, respectively) (Nagae, et al., 2011; Saxonov, et al., 2006). The two 
distributions overlap, and promoters in the overlapping region form a class of intermediate 
CpG content promoters (ICP, or “weak” CpG-promoters) (Weber, et al., 2007).   
The majority of CpG sites are cytosine-methylated in genomic DNA with percentages 
between 60%~90% depending on the source reports (Gruenbaum, et al., 1981; Razin, et al., 
1984). The exceptions are CpG islands, where CpG sites are usually unmethylated. It follows 
that HCPs are usually undermethylated while LCPs are highly methylated at a level not 
different from the rest of genomic DNA. According to a genome-wide study (Weber, et al., 
2007), 65% of established human promoters belong to the HCP class, but only 25% of the 
hypermethylated promoters are from this category. On the other hand, only 25% of 
promoters classify as LCP, but 42% of hypermethylated promoters belong to the LCP group. 
Notably, matching the promoter CpG density and methylation data with gene expression 
information in public databases has revealed that the undermethylated HCP-controlled 
genes often perform general “housekeeping” functions and are expressed in many tissues, 
while the highly methylated LCPs are frequently associated with tissue–specific functions 
and exhibit more restricted expression (Nagae, et al., 2011; Saxonov, et al., 2006; Weber, et 
al., 2007). Genome-scale analyses have also demonstrated that a small percentage of HCPs 
(3-4%) is hypermethylated in somatic cells (Meissner, et al., 2008; Shen, et al., 2007; Weber, et 
al., 2007). More detailed examination of this subgroup has shown that it is enriched in 
germline-specific genes and in germline-derived cells, where the genes function, these HCPs 
are undermethylated. Collectively the above relationships between CpG density, 
methylation level and expression suggest that hypermethylation of HCPs is incompatible 
with gene activity and controls the tissue specific expression of a small group of genes in 
differentiated cells. The experimentally determined genome-wide relationship between CpG 
rich (HCP and ICP) promoter activity and methylation level supports this possibility 
(Weber, et al., 2007). The role of CpG methylation in controlling LCP-associated gene 
activity may be similar, but has been demonstrated only recently as discussed below.  
Illingworth et al. (Illingworth, et al., 2008) devised a method to detect CpG islands 
experimentally and determine their methylation levels. They have found that about half of 
the islands overlap with annotated transcription start sites, the rest being intragenic and 
intergenic. Interestingly, these non-promoter CpG islands were methylated at a much higher 
frequency than annotated HCPs, and tissue-specific methylation was also more frequent. In 
another genome-wide study, methylation of intragenic CpG islands was found to correlate 
positively with the level of expression of the host gene (Straussman, et al., 2009). Therefore 
the possibility exists that many “non-promoter” CpG islands actually span unannotated 
transcription start sites and function as HCPs controlling the production of regulatory 
(suppressive) non-coding RNAs (Morris, 2009a, 2009b)  in a tissue-specific and methylation-
sensitive fashion. Thus, some or most of the unmethylated HCPs may be regulated 
indirectly by methylation-sensitive CpG island promoters in a manner analogous to 
imprinted genes (Latos & Barlow, 2009).  
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Immunoprecipitation-based genome-wide analysis of promoters showed relatively high 
methylation levels of LCPs without significant relationship to promoter activity (Weber, et 
al., 2007). Since LCPs control many genes with tissue specific expression and function, this 
issue required further study. Nagae et al. used a sensitive beadarray technique 
(HumanMethylation27 BeadChip, Illumina) to determine the methylation level of 27 587 
individual CpG sites in 14 475 promoters in 21 normal human tissue samples (Nagae, et al., 
2011). As expected, HCPs were generally hypomethylated in all tissues. The CpG poor LCPs 
were methylated more extensively; however, the methylation level of individual LCPs 
varied widely between tissues. Gene ontology (GO) analysis showed that the 
hypomethylated, but not hypermethylated, LCPs in each tissue belonged to genes closely 
related to tissue specific functions. Furthermore, the expression of representative sets of 
tissue specific hypomethylated genes was increased in the corresponding tissue, while 
hypermethylation (relative to the average) had no relationship to expression. These 
methylation-sensitive LCPs were particularly enriched in transcription factor recognition 
motifs. Thus, LCPs are also regulated negatively by methylation, possibly by blocking 
transcription factor binding/activity at critical CpG sites. These results, together with the 
additional observation that many tissue-specific hypomethylated LCPs were fully 
methylated in embryonic stem cells and induced pluripotent cells (Nagae, et al., 2011), raise 
the possibility that terminal differentiation is associated with the demethylation of tissue-
specific LCP-driven genes.  
Genomic imprinting, which suppresses either the paternal or the maternal alleles of defined 
gene clusters, and X chromosome inactivation in females are the best characterised examples 
of gene silencing by CpG methylation (Heard, et al., 1997; Illingworth, et al., 2008; Latos & 
Barlow, 2009). Both of these processes are integrated with development and will be 
discussed further below. 
Finally, small, but detectable, non-CpG (notably CpA and CpT) methylation has been 
reported in mammalian genomes (Kouidou, et al., 2006; Ramsahoye, et al., 2000; White, et 
al., 2002). Bernard H. et al (Ramsahoye, et al., 2000) reported that 15~20% of total cytosine 
methylation in ESCs (embryonic stem cells) is at non-CpG sites, mostly at CpA and, to a less 
extent, at CpT. However, the establishment and maintenance of non-CpG methylation is 
unclear. It is reported that similar to CpG site methylation, non-CpG site methylation is also 
mediated by Dnmt3 and maintained by Dnmt1 (Grandjean, et al., 2007; Ramsahoye, et al., 
2000; White, et al., 2002).  
5. Mechanisms of DNA methylation-mediated transcriptional repression  
As described in the previous section, DNA methylation is strongly associated with the 
suppression of gene expression. Two main mechanisms are involved in the repression and 
they are biologically relevant. First, DNA methylation has been shown to directly interfere 
with the binding of some transcription factors to the CpG sites. It is known that many 
factors bind CpG-containing regions to stimulate gene expression, and a number of these 
consensus binding motifs (CRE, ETS, NRF-1, E-Box, AP2, etc, see ref. (Rozenberg, et al., 
2008) and references therein) fail to bind or function if the CpG sites are methylated 
(Campanero, et al., 2000; Pierard, et al.; Sunahori, et al., 2009).  
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The second mechanism involves recruitment of methyl-CpG-binding domain (MBD) 
proteins, which selectively recognize methylated CpG sites and silence associated genes by 
recruiting transcriptional corepressor complexes involving histone deacetylases (HDACs) 
and histone methyltransferases (P. A. Jones & Laird, 1999; Munro, et al.; Prendergast & Ziff, 
1991). A family of MBD proteins has been identified that include MeCP2, MBD1, MBD2, 
MBD3 and MBD4 (Hendrich & Bird, 1998). The MBD domains show homology among these 
proteins, whereas the transcription repression domains (TRD) identified in MeCP2, MBD1 
and MBD2 are non-conserved.  
MeCP2 is the founder of the MBD protein family, which represses gene expression by 
recruiting the corepressor mSin3A that interacts with HDAC1 (P. L. Jones, et al., 1998; Nan, 
et al., 1998). Mutation in the MeCP2 gene in the X-chromosome accounts for the vast 
majority of RTT (Rett) syndrome cases, which is a postnatal neurodevelopment disorder 
characterized by mental retardation, ataxia, hand stereotypes, seizures, and breathing 
irregularities (Amir, et al., 1999). MeCP2 represses gene expression by recruiting mSin3A, 
which interacts with HDAC1 (P. L. Jones, et al., 1998; Nan, et al., 1998).  Mammalian MBD3 
does not directly bind to CpG sites because of a mutation of the MBD (Saito & Ishikawa, 
2002). However, it is essential for embryogenesis, since targeted deletion of MBD3 results in 
mouse embryo lethality (Hendrich, et al., 2001). There is little evidence of MBD4 acting as a 
transcription repressor, instead, it is an important thymine DNA glycosylase involved in 
DNA repair (Hendrich, et al., 1999).  
6. 5-hydroxymethylcytosine (5hmC), the sixth base of mammalian DNA  
Besides 5-methylcytosine (5mC), mammalian genomic DNA also contains 5-
hydroxymethylcytosine (5hmC), which is the oxidative modification of 5mC and is 
recognized as the sixth base of DNA. The first report of 5hmC in mammals was in 1972 
(Penn, et al., 1972). Little attention, however, was attracted because of the lack of 
consistently reproducible data (Kothari & Shankar, 1976). Two recent reports, however, 
brought 5hmC back into the limelight (Kriaucionis & Heintz, 2009; Tahiliani, et al., 2009). 
Kriaucionis and Heintz detected 5hmC in mouse Purkinje cells and granule cells as 0.6% and 
0.2% of total nucleotides, respectively. Tahiliani et al detected an even lower percentage of 
5hmC in mouse ES cells, only 0.03% of all bases. After these discoveries, a number of 
methods were developed to distinguish 5hmC from 5mC, since traditional bisulfite 
sequencing or methylation-sensitive restriction digestion do not differentiate between the 
two modified bases (Huang, et al., 2010; Jin, et al., 2010).  
Munzel et al (Munzel, et al., 2010) have found that 5hmC is widely distributed in mouse 
brain. Relatively high levels of 5hmC were found in areas responsible for higher cognitive 
functions, such as in hippocampus and cortex. The level of 5hmC in mouse hippocampus  
increased by approximately 75% in 90-day-old mice compared to in one-day-old mice, 
which was unrelated to oxidative DNA damage due to aging. Coincidentally, Song et al 
(Song, et al., 2010) reported an increase of 5hmc level from 0.1% of total nucleotides in post-
natal day 7 to 0.4% in adult age in mouse cerebellum tissue. 5hmC is speculated to play an 
important role in central nervous system development.  
The generation of 5hmC is based on the pre-existence of 5mC (Ficz, et al., 2011; 
Szwagierczak, et al., 2010; Williams, et al., 2011). The conversion of 5mC to 5hmC is 
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achieved by the ten-eleven translocation (TET) enzyme family that has been identified in a 
homology search using the sequences of JBP1 and JPB2, which are responsible for 
hydroxylation and glucosylation of the 5-methyl group of thymine (Tahiliani, et al., 2009; 
Yu, et al., 2007). Three members of TET family have been uncovered, TET1, TET2 and TET3. 
Lately, the TET protein has been reported to catalyse the generation of 5-carboxylcytosine 
(5caC) and 5-formylcytosine (5fC), which might be involved in the active demethylation of 
DNA (He, et al., 2011; Ito, et al., 2011).   
The functional consequences of the 5hmC modification are still unclear. Like other 
modifications, it may alter chromatin organization by recruiting or excluding factors that 
influence transcription (S. C. Wu & Zhang, 2010). Importantly, it is proposed to be involved 
in the enigmatic process of DNA demethylation. First, 5hmC cannot be recognised by 
Dnmt1. Therefore, it interferes with the Dnmt1-mediated maintenance of DNA methylation, 
which results in passive demethylation during replication (Valinluck & Sowers, 2007). 
Second, it may be a key intermediate in the controversial process of active demethylation. 
We discuss this in detail in the section on DNA demethylation below. Additionally, it was 
reported that the MBD family, including MeCP2, MBD1, MBD2 and MBD4, have 
significantly reduced affinity for CpG sites that are hydroxymethylated (Jin, et al., 2010; 
Valinluck, et al., 2004). Given the repressive transcriptional role of MBD proteins and their 
interactions with histone modifying enzymes, the conversion from 5mC to 5hmC could 
reduce MDB activity at the affected sites and change epigenetic patterns to promote 
transcriptional activity.  
7. DNA demethylation in the zygote 
DNA methylation is a stable but not irreversible epigenetic mark. The reverse process, DNA 
demethylation, has been observed in specific contexts. Genome-wide DNA demethylation 
occurs after fertilization, when the existing DNA methylation pattern of the paternal and 
maternal genomes is erased and the epigenetic state of the early embryo is reset (Hajkova, et 
al., 2002; Mayer, et al., 2000).  
The loss of DNA methylation is achieved in two distinct ways, passive demethylation and 
active demethylation. Passive demethylation occurs due to replication-dependent inhibition 
or absence of Dnmt1, which results in lack of DNA methylation in the newly synthesized 
DNA. Active demethylation refers to actively removing the methyl group, the methylated 
cytosine or the whole nucleotide; the mechanisms in mammals are still poorly understood 
and controversial. 
Various mechanisms of active demethylation in mammals have been proposed, including 
direct enzymatic removal of the methyl group from 5mC, nucleotide-replacement reaction 
and further modifications of 5mC followed by a base excision repair (BER) pathway.  
Direct removal of the methyl group from 5mC seems to be the most direct way to achieve 
demethylation, however, a robust enzyme activity of a “demethylase”is needed to break the 
strong carbon-carbon bond. One of the MBD proteins, MBD2, is the first to be identified to 
serve as a DNA demethylase. MBD2 was shown in vitro to remove the methyl group and 
release in the form of methanol (Bhattacharya, et al., 1999). However, this mechanism was 
strongly contested because several groups failed to reproduce the enzyme activity in 
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different genes (Boeke, et al., 2000; H. H. Ng, et al., 1999). Moreover, it has been revealed 
that MBD2-null mice still exhibit normal pattern of DNA methylation (Hendrich, et al., 
2001), and the active demethylation of the paternal genome still occurs normally in zygote 
deficient in MBD2 (Santos, et al., 2002), which suggests that the major demethylation 
mechanisms do not involve MBD2. 
The nucleotide-replacement reaction is commonly involved in substantial DNA repair 
following damage due to exposure to radiation or chemicals. The basic steps include dual 
incisions flanking the lesion, release of a 24~32 nucleotide oligomer and replacement with 
new synthesized nucleotides followed by ligation (Sancar, et al., 2004).  A DNA repair 
protein, growth arrest and DNA-damage-inducible 45a (Gadd45a), was reported to 
participate in active demethylation. Knockdown of Gadd45a leads to hypermethylation and 
gene silencing, whereas overexpression results in activation of loci-specific gene and global 
demethylation (Barreto, et al., 2007). Again, other studies failed to confirm the role of 
Gadd45a in active DNA demethylation, which raises doubts on this pathway (Engel, et al., 
2009; Jin, et al., 2008).  
The DNA glycosylase and base excision repair (BER) system mediated active demethylation 
is the main mechanism utilized by plants. The key steps involve a group of 5mC 
glycosylases (including ROS1, DME, DML2 and DML3) removing the methylated cytosine, 
followed by a BER pathway to fill in the gap with an unmethylated cytosine (J. K. Zhu, 
2009). However, evidence supporting this mechanism in mammals seems less convincing 
due to the lack of 5mC glycosylase in mammalian cells. Although MBD4 and thymine DNA 
glycosylase (TDG), two confirmed TG mismatch glycosylases, have been reported to have 
weak activity against 5mC: G in vitro, this activity is 30~40 fold lower compared to the T: G 
mismatch (B. Zhu, Zheng, Angliker, et al., 2000; B. Zhu, Zheng, Hess, et al., 2000). In 
addition, deletion of MBD4 does not affect the active demethylation of the paternal genome 
in zygotes, which challenges the possibility that MBD4 is the principal DNA demethylase 
operating after fertilization (Santos & Dean, 2004). 
It has also been proposed that active demethylation can be achieved by the deamination of 
5mC to generate T followed by the BER pathway to replace the T with an unmethylated 
cytosine.  The activation-induced deaminase (AID) and apolipoprotein B mRNA-editing 
catalytic polypeptides (Apobec) family are able to deaminate 5mC (Morgan, et al., 2004). 
Recent work has also shown that AID is necessary for promoter demethylation of the OCT4 
and NANOG genes in the reprogramming of human somatic cells to pluripotent stem cells 
(Bhutani, et al., 2010). However, AID is active on single-stranded, but not on double-
stranded DNA and its affinity to 5mC is 10-fold lower than to unmethylated cytosine 
(Bransteitter, et al., 2003). Surprisingly, Dnmt3a and Dnmt3b have also been shown to 
possess 5mC deaminase activity in vitro, which may be involved in the CpG 
methylation/demethylation cycling observed at the pS2/TFF1 gene promoter after estrogen 
stimulation (Metivier, et al., 2008). More work needs to be done to uncover the mechanism 
and significance of these dual functions.  
Recently, an oxidative-deamination-BER pathway (Fig.2) of active demethylation has been 
described with 5hmC as the key intermediate. The TET proteins have been shown to oxidize 
5mC to generate 5hmC that is acted upon by the AID and Apobec family deaminases to 
generate 5hmU for subsequent processing by BER (Guo, et al., 2011). TDG exhibits robust 
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glycosylase activity on the 5hmUG mismatch to remove 5hmU and the gap is filled by an 
unmethylated cytosine. Both knockout and inactive point mutations of TDG result in mice 
embryo lethality and developmental defect (Cortellino, et al., 2011). In addition, it has been 
demonstrated that 5mC and 5hmC can be further modified to 5-formylcytosine (5fC) and 5-
carboxylcytosine (5caC) by TET proteins. The existence of 5fC and 5caC has been identified 
in mice ES cells (Ito, et al., 2011). TDG is able to recognize and cleave 5caC and 5fC to initiate 
the BER pathway (He, et al., 2011; Maiti & Drohat, 2011). It is also proposed that an 
unknown decarboxylase enzyme is involved in the conversion from 5caC to C, without the 
participation of BER (Ito, et al., 2011). 
 
Fig. 2. Pathways of active DNA demethylation. 
5mC can be hydroxylated by TET to generate 5hmC, which can be further oxidized to 5fC 
and 5caC. Alternatively, 5hmC can be deaminased by AID and Apobec family members to 
generate 5hmU. Base excision repair (BER) will be initiated by modified bases, eventually 
replacing them with cytosine. 
8. Dynamic of DNA methylation in development 
Extensive reprogramming of epigenomes occurs during early development, allowing  
cells to attain a totipotent developmental potential. Remodeling of DNA methylation 
patterns, including a genome-wide demethylation with imprinted genes as exceptions, is 
observed in mammalian zygotes, primordial germ cells and early embryos. This process is 
essential for erasure of the previous germ line DNA methylation pattern and 
establishment of new marks.  
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8.1 Asymmetric genome-wide demethylation  
The genomes of sperm and oocytes are organised differently. The genome of sperm is 
packaged with protamines, while oocytes are packaged with histones. At fertilization, a 
rapid exchange from protamine to histone occurs in the paternal genome. As early as a few 
hours after fertilization, a remarkable asymmetric DNA demethylation occurs in the two 
parental genomes, although they are exposed to the same oocyte cytoplasm. The paternal 
genome undergoes a genome-wide demethylation before the first cell division cycle, which 
is therefore considered active demethylation, while the maternal genome is protected from 
this reprogramming (Oswald, et al., 2000). Notably, some regions of the paternal genome are 
still resistant to demethylation, including imprinted genes. 
Recent work from two laboratories has linked this loss of 5mC to its conversion to 5hmC 
(Iqbal, et al., 2011; Wossidlo, et al., 2011). Analysis of mouse, rabbit and bovine embryos 
showed a strong presence of 5hmC in the paternal pronucleus, while the amount of 5mC 
decreased. On the other hand, 5hmC in the maternal pronucleus was nearly undetectable, 
compared to the abundance of 5mC. This suggests that 5mC in the paternal, but not in the 
maternal, pronuclei is converted to 5hmC possibly as part of the active demethylation 
pathway outlined above. The distribution differences of 5hmC in the two parental 
pronucleus were maintained towards the two-cell stage. It was also shown that TET3 
contributed significantly to this conversion. Tet3 exhibits extremely high expression levels in 
oocytes and zygotes compared to the very low levels of TET1 and TET2. Levels of TET3 
decrease dramatically at the two-cell stage, which stops the further increase of 5hmC levels. 
Knockdown of TET3 results in substantial reduction of 5hmC and a strong increase of 5mC 
in the paternal pronucleus. Consistent with the lack of active demethylation, the maternal 
pronucleus is inaccessible to this TET3-mediated conversion from 5mC to 5hmC. 
Knockdown of TET3 has little effect on the 5mC signal in the maternal pronucleus.  
An intriguing question is how the maternal pronucleus is protected from active 
demethylation. It has been proposed that the PGC7/Stella gene is important for this 
protection, since the maternal genome of the PGC7/Stella-null zygote undergoes significant 
demethylation (Coward, et al., 2009). It has also been reported that the absence of 
PGC7/Stella leads to the increase of 5hmC in the maternal pronucleus, which suggests 
PGC7/Stella as a protector of 5mC against oxidation (Wossidlo, et al., 2011). The mechanism 
of the protection, however, remains unclear. A further question is why the presence of 
PGC7/Stella does not protect the paternal pronucleus from demethylation. Structural 
differences may be the answer.  
The maternal genome undergoes gradual passive demethylation during the several cell 
divisions leading towards blastocyst formation due to a lack of maintenance of methylation 
in the zygote. Imprinted genes are resistant to this process, as well as to the active 
demethylation in the paternal genome. 
8.2 Genomic imprinting 
Although extensive DNA methylation reprogramming occurs in early development, a 
number of genes are resistant to this change including imprinted genes. Gene imprinting is 
an enigmatic phenomenon that causes genes to be expressed in a parental-origin-specific 
way, wherein either the paternally or the maternally inherited allele is silenced. 
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Approximately 60 imprinted genes have been identified in the human (R. K. Yuen, et al., 
2011). Genomic imprinting plays a significant role in normal development through 
regulating embryo growth, placental function and neurobehavioral processes (McGrath & 
Solter, 1984; Surani, et al., 1984). Abnormal expression of imprinted genes has been 
demonstrated to be associated with a few human diseases, including the Prader-Willi 
syndrome (PWS), the Angelman syndrome (AS), the Silver-Russell syndrome (SRS) and the 
Beckwith-Wiedemann syndrome (BWS) (Paulsen & Ferguson-Smith, 2001). 
DNA methylation is the key feature of imprinted gene clusters. The regions at imprinted 
loci marked by DNA methylation (DMRs) are methylated only on one allele. The product 
of one gene in an imprinted cluster is often a non-coding RNA, which regulates the 
expression of the other members of the cluster in cis. The DMRs established through the 
germ line often coincide with crucial imprinting control regions (ICRs), which if 
methylated, suppress the expression of the regulatory non-coding RNA. During 
development of primordial germ cells, DNA methylation is erased and then re-established 
in the process of oogenesis and spermatogenesis to generate gender specific germline 
imprinting patterns. Once established, the imprinted status will be stably maintained in 
all somatic lineages. Other DMRs acquire this methylation status after fertilization and are 
often tissue-specific (J. R. Mann, 2001). The mechanisms of the resistance of imprinted 
genes to epigenetic reprogramming post-fertilization are complex and still not fully 
characterised (see ref. (Weaver, et al., 2009)for review). A few factors have been suggested 
to be involved, including the DNMT1 isoforms DNMT1o and DNMT1s, MDB3 and 
PGC7/Stella, which also participates in the protection of the maternal genome from post-
fertilization active demethylation (Nakamura, et al., 2007). ZFP57, which is a KRAB zinc 
finger protein, has been demonstrated to be required for maintenance of maternal 
methylation imprints at the Snrpn imprinted region. It is also important for maintenance 
of genomic imprinting at multiple DMRs (X. Li, et al., 2008).  
Dysregulation of imprinted genes are associated with a number of human syndromes that 
will be discussed in the following sections.  
8.3 DNA methylation in germ cell development 
After implantation of the blastocyst, a subset of pluripotent cells in the epiblast generate 
primordial germ cells (PGCs), the origin of both oocytes and spermatozoa, in responding to 
signals from extraembryonic ectoderm and visceral endoderm. Two critical transcription 
factors, B-lymphocyte maturation-induced protein1 (BLIMP1, also known as PR domain 
zinc finger protein1)) and PRDM14 are essential for specification of PGCs and suppression 
of somatic gene expression (Ohinata, et al., 2005; Saitou, 2009).  
When the germ cell fate is established, the level of global DNA methylation is similar to that 
observed in surrounding epiblast cells (Seki, et al., 2005). The cells then gradually migrate to 
the genital ridge accompanied by significant reprogramming of epigenetic marks. A 
substantial reduction of genome-wide DNA methylation has been observed after 
specification of germ cells. However, it is not until arriving at genital ridge that DNA 
methylation including parental imprinting marks is extensively erased (Hajkova, et al., 
2002). Due to the presence of Dnmt1 for most of the period, this widespread demethylation 
is considered to be active, replication-independent. BER pathway has been reported to be 
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involved in the process. Interestingly, significant expression of TET1 gene has been detected 
in mouse PGCs, indicating a role of 5hmC as an intermediate in this active demethylation 
(Hajkova, et al., 2010). 
In female mammals, one of the two copies of X chromosomes is inactivated to balance the X-
linked gene dosage between females and males. The process is termed X chromosome 
inactivation and is stably maintained in female somatic cells by the DNA methylation mark 
at the silenced genes. In female germ cell development, the inactivated X chromosome is 
reactivated. This reactivation occurs during migration and gonadal colonization, which 
coincides with genome-wide DNA demethylation.  
In the global demethylation of PGCs, parental imprinting marks are erased and reset in a 
gender specific fashion. In male germ cells, the new imprints are progressively established 
during late fetal development and are not completed until the mature sperm stage (J. Y. Li, 
et al., 2004). In contrast, the initiation of methylation imprints occurs postnatally during the 
oocyte growth phase (Lucifero, et al., 2004). The Dnmt3 family is responsible for the de novo 
methylation of imprinted DMRs. Knockout of Dnmt3a and Dnmt3b in mouse germ cell line 
revealed that although they are both involved, Dnmt3a plays the major role in establishment 
of imprinting with Dnmt3L as a critical co-factor (Kaneda, et al., 2004; Kato, et al., 2007). 
8.4 DNA methylation in cellular differentiation during development 
The evidence summarized above demonstrates that DNA (CpG) methylation is a critically 
important component of all aspects of cellular differentiation from fertilization to 
senescence. At the molecular level, CpG methylation of DNA results in gene silencing. X-
chromosome inactivation and genomic imprinting are well characterised, specific examples 
of this phenomenon. In the developmental time line, the paternally and maternally inherited 
DNA methylation patterns are quickly erased in the zygote after fertilization by active and 
passive demethylation, respectively. DNA methylation levels in the genome reach a nadir at 
the morula stage (Abdalla, et al., 2009; Weaver, et al., 2009). In the subsequent phase of 
blastocyst formation, a primary differentiation event occurs, giving rise to two distinct cell 
lineages, the inner cell mass (ICM) and the trophectoderm.  The ICM will generate the 
embryo proper as well as extraembryonic endoderm and mesoderm, while the 
trophectoderm will form the chorion and the placenta (Fleming, 1987). During blastocyst 
differentiation, a wave of de novo methylation is carried out by Dnmt3 family members, 
which leads to different methylation patterns between the ICM and trophectoderm. This 
occurs around the time of implantation. The main de novo Dnmt at the blastocyst stage, 
Dnmt3b, has been specifically localized in the ICM of mouse blastocysts (Watanabe, et al., 
2002). Thus the pluripotent stem cells of the ICM show much higher levels of DNA 
methylation compared to the trophectoderm; and this lineage-based methylation difference 
persists into the later stage of development, placenta and embryo proper (Santos, et al., 
2002). The embryonic stem cells lose cell lineage restriction and differentiate into trophoblast 
cells after the deletion of Dnmt1, which implicates DNA methylation as the key factor to 
achieve cell lineage stability. At the gene expression level, the robust difference in 
methylation of a transcription factor encoding gene, Elf5, has been shown to be critical in cell 
lineage fate. It is hypermethylated and repressed in the embryonic cell lineage but 
hypomethylated and expressed in the trophoblast compartment (R. K. Ng, et al., 2008).  
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The general genomic pattern of CpG methylation is established during ICM differentiation 
in the blastocyst at the time of implantation. Thus, CpG-rich promoters (HCPs and ICPs) 
remain unmethylated, probably due to the protective effect of cis-acting sequence motifs 
(Straussman, et al., 2009). On the other hand, CpG-poor promoters (LCPs), often controlling 
genes with tissue-specific expression are highly methylated possibly to prevent untimely 
expression in the pluripotent embryonic stem cells (ESCs) (Nagae, et al., 2011). The 
exceptions include the pluripotency and ESC-self renewal-associated genes, which often 
belong to the LCP class but are unmethylated in ESCs (e.g. Nanog, Pou5f1, Gdf3 (Straussman, 
et al., 2009)). Recent work suggests that the demethylation of Nanog is a TET1-dependent 
active process maintaining Nanog expression in mouse ESCs (Ito, et al., 2010). This example 
raises the possibility that other LCP class promoters also undergo targeted active 
demethylation in ESCs. 
Differentiation of ESCs to various somatic cell types is also associated with changing DNA 
methylation of functionally relevant promoters. A small proportion of HCPs, controlling 
germline-specific genes, becomes methylated de novo in all cell types except for germline-
derived cells (Shen, et al., 2007; Weber, et al., 2007), where they are expressed. Similarly, 
ESC-specific HCP-controlled genes are shut down in differentiated cells by de novo 
methylation of the promoter (Straussman, et al., 2009). CpG-island sequences at gene loci 
controlling development, such as OSR1, PAX6 and HOXC are frequently methylated in 
normal tissues; however, these methylations do not appear to correlate closely with gene 
expression levels (Illingworth, et al., 2008). The mechanisms that select these HCPs for 
methylation are unclear, but may involve other epigenetic marks such as histone 
modifications (Meissner, 2010). CpG-poor promoters (LCPs) undergo tissue-specific 
demethylation during differentiation, which correlates with the increased activity of 
functionally relevant genes (Nagae, et al., 2011). The mechanism of this gene and tissue 
selective process is unclear; it may involve the newly discovered TET-dependent active 
demethylation, or it may be passive demethylation driven by transcription factor binding to 
the promoter, which may prevent maintenance  methylation after cell division.  
The pattern of DNA methylation is considered stable after differentiation as long as cellular 
identity is maintained. Recent studies, however, have shown that the CpG methylation 
pattern changes during life. Christensen et al., (Christensen, et al., 2009) analysed 1413 CpG 
sites at 773 genes in 217 healthy individuals, and observed that CpG island methylation 
levels increased, while non-CpG island methylation levels decreased with age. 
Environmental factors, such as tobacco smoking, also affected CpG methylation levels in 
individuals. Yuen et al. (R. K. C. Yuen, et al., 2011) compared the methylation status of 1315 
CpG loci in 752 genes from five somatic tissues between normal second trimester fetuses 
and adults. They found tissue-specific differentially methylated regions in 195 loci in the 
fetuses, but only 17% of these were maintained in adults. Further, the methylation status of 
about 10% of the examined sites changed more than 40% between the fetus and the adult. 
These data indicate the plasticity of the tissue-specific DNA methylation patterns and their 
susceptibility to environmental conditions.  
9. DNA methylation and human diseases 
Age and the environment have key importance in many disease processes; therefore it is not 
surprising that aberrant DNA methylation contributes to a variety of pathologies. Epigenetic 
www.intechopen.com
 
Embryology – Updates and Highlights on Classic Topics 
 
158 
changes have been firmly established as components of malignant transformation; however, 
this large area of investigation has been recently reviewed (Brait & Sidransky, 2011) and is 
beyond the scope of this chapter (Esteller, 2011). In recent years, the relationship between 
adverse intrauterine conditions at early development and increased risk of post-natal 
diseases has been recognized.  
Chronic diseases including cardiovascular disease, type 2 diabetes and obesity are 
associated with abnormal intrauterine growth and development (Hales & Barker, 1992; 
Osmond, et al., 1993; Rich-Edwards, et al., 2005). This relationship has been termed as the 
Developmental Origins of Health and Disease (DOHaD). The hypothesis of DOHaD 
indicates a high degree of phenotypic plasticity during development. Epigenetic regulation 
have been suggested to be the most attractive mediator between transient environmental 
exposures and sustained changes at gene, cell or tissues levels. Especially, aberrant DNA 
methylation of key disease-associated genes has been suggested to be involved in DOHaD.  
9.1 Role of maternal diet 
Maternal malnutrition is a comparatively well characterized factor influencing DNA 
methylation of genes in the context of DOHaD (See ref.  (Burdge & Lillycrop, 2010) for 
review). Further, several studies have reported that altered maternal intake of folate is 
linked to change of DNA methylation in the offspring (Kim, et al., 2009; Waterland, et al., 
2006; Waterland & Jirtle, 2003). Folate deficiency has been strongly associated with 
incomplete closure of the neural tube. Suppression of methylation cycles, which can be 
the consequence of insufficient maternal intake of folate, causes a high risk of neural tube 
defect in mice (Dunlevy, et al., 2006). Recently, it has been reported that reduced maternal 
folate status may contribute to the development of colorectal cancer in adult offspring 
(McKay, et al., 2011). Maternal folate depletion is associated with a locus-specific drop of 
DNA methylation in the Slc39a4 gene in fetal gut. The Slc39a4 gene has been shown to be 
hypomethylated in colorectal cancer. Thus the deficiency of folate in pregnancy might 
have consequence for colorectal cancer development if the altered methylation is 
sustained into adulthood.  
Folate supplementation during pregnancy has been widely used to reduce the incidence of 
neural tube defects. It has been suspected, however, that folate may have adverse effects 
inducing allergic diseases such as asthma and eczema by altering the methylation status of 
DNA in the offspring (Dunstan, et al., 2011; Hollingsworth, et al., 2008).  
Apart from nutrition, maternal behaviour (level of care, depression) has also been shown to 
alter the methylation of steroid receptor gene promoters in the offspring and influence 
steroid hormone sensitivity later in life (Champagne, et al., 2006; Oberlander, et al., 2008). 
9.2 Infection and inflammation 
Maternal infections such as urinary tract and periodontal infection have been correlated 
with pregnancy complications (reviewed in ref. (Conde-Agudelo, et al., 2008)). Treatment of 
periodontal disease during pregnancy was reported to reduce the rate of preterm birth and 
lower incidence of low birth weight (Polyzos, et al., 2009). The mechanisms underlying this 
relationship has been linked to abnormal DNA methylation patterns (Bobetsis, et al., 2007). 
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Specifically, it has been shown in murine placenta tissues that maternal oral infection caused 
by C. rectus can induce hypermethylation in the promoter of imprinted insulin-like growth 
factor 2 (Igf2) gene. Deficiency of Igf2 gene expression leads to reduction of placental growth 
and restricted fetal growth (Constancia, et al., 2002). This suggests that DNA altered 
methylation (and expression) of key genes can contribute to infection-associated adverse 
pregnancy outcomes such as intrauterine growth restriction (IUGR).  
Loss of DNA methylation in T cells has been shown in systemic lupus erythematosus (SLE), 
an autoimmune disease affecting multiple organs. A significant decrease of genomic DNA 
methylation with reduced Dnmt1 levels has been reported (Richardson, et al., 1990).  
Specific genes relevant to the SLE phenotype are also hypomethylated in T cells of SLE 
patients compared to their normal counterparts (Lu, et al., 2002; Oelke, et al., 2004). The 
DNA methylation inhibitor 5-aza-2’-deoxycytidine causes autoreactivity of T cells in vitro as 
well as an SLE-like disease in vivo, suggesting that T cell DNA hypomethylation is involved 
in the autoantibody response in SLE (Quddus, et al., 1993).   
9.3 Endometriosis 
Dysregulation of DNA methylation in several genes has been reported in endometriosis, a 
common gynecological condition affecting women of reproductive age. The promoter  
of progesterone receptor B (PR-B) has been shown to be hypermethylated in 
endometriosis, which may be responsible for PR-B down-regulation and the notable 
progesterone resistance (Y. Wu, et al., 2006). The promoter of estrogen receptor 2 (ESR2)  
is hypomethylated in endometriosis, which may result in the significantly increased  
level of estrogen receptor expression compared to the stromal cells in  endometrium (Y. 
Wu, et al., 2006).  
9.4 Disruptions of imprinting 
The human chromosome 11p15.5 harbours a cluster of imprinted genes including paternally 
expressed insulin-like growth factor 2 (IGF2) and maternally expressed H19 and KCNQ1 
(KVLQT1) genes (Paulsen, et al., 1998). DNA methylation abnormalities at 11p15.5 can cause 
two distinct growth disorders, the Beckwith–Wiedemann (BWS) and the Silver–Russell 
(SRS) syndromes. BWS is characterized by fetal and postnatal overgrowth, macroglossia, 
neonatal hypoglycaemia and an increased incidence of childhood tumors. SRS is 
characterized by severe intrauterine and postnatal growth retardation, dysmorphic facial 
features, feeding difficulties, and body and limb asymmetry. DNA methylation defects 
account for approximately 60–70% of BWS and SRS patients (Demars, et al., 2011). Two 
imprinting control regions, ICR1 and ICR2, control the differential expression of imprinted 
genes at 11p15.5. Both the paternal and maternal alleles of ICR1 and ICR2 are methylated in 
normal cells. The DNA methylation defects at ICR1 is usually the hypermethylation of the 
maternal allele, leading to both BWS and SRS, whereas DNA methylation defects at ICR2 
usually involve loss of maternal-allele-specific DNA methylation, which results in only BWS 
(Robertson, 2005).  
Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are two distinct neurogenetic 
disorders in which the same domain on chromosome 15 is affected. AS is caused by the loss 
of the maternally expressed gene, UBE3A, which is only imprinted in the brain. Loss of 
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maternal DNA methylation or maternal ICR deletion is involved in the imprinting defects, 
which account for ~5% of AS.  
9.5 ARTs and imprinting defects 
In the setting of infertility, the use of assisted reproductive technologies (ARTs) has been 
growing. Although the majorities of the children conceived with ARTs develop normally, 
recent studies have suggested a possible link between ARTs and genomic imprinting 
disorders.  Cox et al. (2002) have reported that two children who were conceived by 
intracytoplasmic sperm injection (ICSI) develop AS and a third case has been reported by 
Orstavik et al. (2003). A loss of methylation on the maternal allele at SNRPN locus have been 
shown in all three children, while the paternal allele has normal methylation pattern, 
suggesting a relationship between AS and an ICSI associated imprinting defect. A few 
studies have also pointed to the association between the occurrence of BWS and in vitro 
fertilization (IVF) and ICSI. Hypomethylation of KCNQ1OT1 due to a chromosome 11p15.5 
ICR2 defect as well as an abnormal methylation pattern of H19 have been observed in 
children conceived via ARTs (DeBaun, et al., 2003).  
It has been proposed that in vitro manipulations of several steps involved in conception 
contribute to alteration of the normal imprinting processes. In current ARTs protocols, in 
vitro culturing of embryos is extended until the blastocyst stage before embryo transfer to 
allow high pregnancy rate and reduce the risk of multiple pregnancy. It has been 
demonstrated that culture of preimplantation embryos influences genomic imprinting 
marks (Khosla, et al., 2001; M. R. Mann, et al., 2004). ARTs also involve induced ovulation 
via hormonal stimulation and in vitro maturation of oocytes, which might interrupt the 
natural development of oocytes and the genomic imprinting marks of the maturing oocytes 
(Iliadou, et al., 2011).  
The number of pathological conditions where aberrant DNA methylation is a contributor 
will likely increase as more refined technologies become available for the sensitive, accurate 
and high-throughput determination of CpG methylation at affordable prices. It is reasonable 
to expect that the complex mechanisms underlying CpG methylation, demethylation, 
methylation targeting and methylation protection will offer new therapeutic targets to 
alleviate the consequences of aberrant methylation in disease. 
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